Survodutide: Dosage & Administration
Part of the Survodutide Complete Guide
Research Peptides
Advertiser link — we may earn a commission at no extra cost to you.
Investigational Status (Important Context)
Survodutide (BI 456906) is a dual GLP-1 / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. It is in Phase 3 clinical development as of 2026 — Phase 3 SYNCHRONIZE trials for obesity and Phase 3 LIVERAGE trial for MASH (metabolic dysfunction-associated steatohepatitis). It is not FDA-approved for any indication.
Dosing information below is from published Phase 2 trials.[1][2] Clinical-grade survodutide is not commercially available outside trials. Survodutide sold in "research peptide" markets is unregulated and is not the clinical-grade molecule used in Boehringer/Zealand trials. Survodutide is also not on the July 2026 FDA Pharmacy Compounding Advisory Committee 503A bulks list agenda.
Phase 2 Dosage Protocols
| Indication | Trial | Dose Range Tested | Route / Frequency | Trial Duration |
|---|---|---|---|---|
| Obesity | Phase 2 SYNCHRONIZE-1 | 0.6 / 2.4 / 3.6 / 4.8 mg | SC weekly | 46 weeks |
| MASH | Phase 2 (NEJM 2024) | 2.4 / 4.8 mg | SC weekly | 48 weeks |
| Type 2 diabetes | Phase 2 dose-finding | 0.3 / 1.2 / 2.4 / 4.8 mg | SC weekly | 16 weeks |
The 4.8 mg weekly dose has emerged as the lead dose for Phase 3 development. It captures the bulk of efficacy (up to 18.7% weight loss in obesity Phase 2; 83% MASH resolution at the highest dose in MASH Phase 2) while producing tolerable GI side effects with a structured titration schedule.[1]
Dose Escalation Schedule
Like all GLP-1 family drugs, survodutide requires a structured weekly titration to manage GI side effects. The Phase 2 escalation schedule used:
| Week | Dose | Notes |
|---|---|---|
| Week 1–2 | 0.3 mg/week | Acclimation dose |
| Week 3–4 | 0.6 mg/week | Sub-therapeutic; titration step |
| Week 5–6 | 1.2 mg/week | Titration step |
| Week 7–8 | 2.4 mg/week | Lower therapeutic dose |
| Week 9–10 | 3.6 mg/week | Titration step |
| Week 11+ | 4.8 mg/week (target) | Phase 3 lead dose |
If a dose escalation is not tolerated (severe nausea, vomiting, dehydration), hold at the current step for an additional 1–2 weeks before retrying. The schedule is slower than semaglutide's because survodutide's glucagon component adds additional GI burden.
Administration
- Route: subcutaneous injection (clinical formulation is pre-filled auto-injector pen).
- Sites: abdomen, thigh, or upper arm. Rotate sites each week.
- Timing: any day of the week; same day each week for consistent dosing intervals. Any time of day.
- With or without food: not strictly dependent on meals.
- Missed dose: if within 3 days of the scheduled day, take as soon as possible and resume normal schedule. If more than 3 days late, skip and resume the next scheduled dose; do not double-dose.
See the injection technique guide for SC injection technique.
Drug-Interaction Timing
Survodutide shares the gastric-emptying delay characteristic of all GLP-1 family drugs. This affects oral medication absorption:
- Oral contraceptives: absorption may be reduced. Consider backup contraception during initial titration.
- Levothyroxine: separate by at least 30 minutes; monitor TSH after starting.
- Warfarin: monitor INR more frequently during dose changes.
- Narrow-therapeutic-index drugs (digoxin, lithium, anticonvulsants): monitor levels closely.
- Insulin / sulfonylureas: reduce dose to avoid hypoglycemia during titration in diabetic patients.
- Glucagon-related drugs: survodutide has glucagon-receptor activity. Avoid combining with exogenous glucagon (hypoglycemia rescue therapy) without medical supervision.
Duration & Cycling
Long-term continuous use is anticipated, consistent with the GLP-1 class. Phase 2 trial durations ranged from 16 to 48 weeks. Phase 3 trials will likely extend beyond 1 year.
- No cycling required — survodutide does not induce receptor tolerance the way some peptides do.
- Weight regain after discontinuation is expected, as with all GLP-1 family drugs.
- Continuous use is the anticipated maintenance pattern post-FDA approval.
Storage
- Pre-filled clinical pens: refrigerate at 2–8°C until first use. Do not freeze.
- After first use: per pen instructions — typically room temperature up to 30°C for up to 28–30 days.
- Travel: insulated cooler with ice pack for transport. Avoid direct contact with frozen gel packs.
- Visual check: solution should be clear and colorless. Discard if cloudy, discolored, or contains particulates.
For broader storage rules, see the peptide storage guide.